Last reviewed · How we verify
NCT03868904
INSPIRE Continuation Post-Approval Study
trial testing OCS Lung System in Bronchiolitis Obliterans in 220 participants. Completed in 12 October 2021.
12 October 2021
Quick facts
| Lead sponsor | TransMedics |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 220 |
| Start date | 30 June 2019 |
| Primary completion | 12 October 2021 |
| Estimated completion | 12 October 2021 |
| Sites | 17 locations across France, Italy, Belgium, United Kingdom, Germany, Canada, Australia, United States |
Drugs / interventions tested
- OCS Lung System
Conditions studied
- Bronchiolitis Obliterans — all drugs for Bronchiolitis Obliterans →
Sponsor
TransMedics — full company profile →
Who can join
Eligibility, any sex, with Bronchiolitis Obliterans. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03868904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of OCS Lung System
Trials testing the same drug.
- NCT04194398 — OCS Lung Expand Post-Approval Study - Expand Follow-Up Data Collection · completed
- NCT03639025 — OCS™ Lung TOP Registry For Donor Lungs for Transplantation · active not recruiting
Other recruiting trials for Bronchiolitis Obliterans
Currently open trials in the same condition.
- NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
- NCT05922761 — BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) · Phase 2 · recruiting
- NCT04604522 — Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome · recruiting
Other TransMedics trials
Trials by the same sponsor.
- NCT05915299 — US National OCS Heart Perfusion (OHP) Registry · recruiting
- NCT04615182 — Donor After Circulatory Death Heart CAP Trial · NA · completed
- NCT04194437 — OCS Liver DCD Trial · NA · terminated
- NCT04186221 — OCS Liver PROTECT Continued Access Protocol · NA · completed
- NCT05096754 — OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03868904 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TransMedics
- Last refreshed: 7 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03868904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing